Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member under age 65, please register here.

If you are an Medicare or Medicare Supplement member, please register here.

New Options for Affordable Health Insurance
MP 7.03.06 Liver Transplant

Medical Policy    
Section
Surgery
 
Original Policy Date
12/01/95
Last Review Status/Date
Reviewed with literature search/1:2013
 
Issue
1:2013
  Return to Medical Policy Index

Disclaimer

Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.

 


Description

Liver transplantation is currently performed routinely as a treatment of last resort for patients with end-stage liver disease. Liver transplantation may be performed with liver donation after brain or cardiac death or with a liver segment donation from a living donor. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network (OPTN) and the United Network of Organ Sharing (UNOS). The severity of illness is determined by the model for end-stage liver disease (MELD) and pediatric end-stage liver disease (PELD) scores.

Background

Recipients

Liver transplantation is now routinely performed as a treatment of last resort for patients with end-stage liver disease. Liver transplantation may be performed with liver donation after brain or cardiac death or with a liver segment donation from a living donor. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network (OPTN) and the United Network of Organ Sharing (UNOS). The original liver allocation system was based on assignment to Status 1, 2A, 2B, or 3. Status 2A, 2B, and 3 were based on the Child-Turcotte-Pugh score, which included a subjective assessment of symptoms as part of the scoring system. In February 2002, Status 2A, 2B, and 3 were replaced with 2 disease severity scales: the model for end-stage liver disease (MELD) and pediatric end-stage liver disease (PELD) for patients younger than age 12 years scoring systems. In September 2012, OPTN/UNOS published its most recent allocation system, which expanded Status1 to Status 1A and 1B. (1) Status 1A patients have acute liver failure with a life expectancy of less than 7 days without a liver transplant. Status 1A patients also include primary graft non-function, hepatic artery thrombosis and acute Wilson’s disease. Status 1A patients must be recertified as Status 1A every 7 days. Status 1B patients are pediatric patients (ages 0-17 years) with chronic liver disease. Following Status 1, donor livers will be prioritized to those with the highest scores on MELD or PELD. With this allocation system, the highest priority for liver transplantation is given to patients receiving the highest number of points. The scoring system for MELD and PELD is a continuous disease severity scale based entirely on objective laboratory values. These scales have been found to be highly predictive of the risk of dying from liver disease for patients waiting on the transplant list. The MELD score incorporates bilirubin, prothrombin time (i.e., international normalized ratio [INR]), and creatinine into an equation, producing a number that ranges from 6 to 40. The PELD score incorporates albumin, bilirubin, INR growth failure, and age at listing. Waiting time will only be used to break ties among patients with the same MELD or PELD score and blood type compatibility. In the previous system, waiting time was often a key determinant of liver allocation, and yet, waiting time was found to be a poor predictor of the urgency of liver transplant, since some patients were listed early in the course of their disease, while others were listed only when they became sicker. In the revised allocation systems, patients with a higher mortality risk and higher MELD/PELD scores will always be considered before those with lower scores, even if some patients with lower scores have waited longer. (2) Status 7 describes patients who are temporarily inactive on the transplant waiting list due to being temporarily unsuitable for transplantation.

Donors

Due to the scarcity of donor livers, a variety of strategies have been developed to expand the donor pool. For example, split graft refers to dividing a donor liver into 2 segments that can be used for 2 recipients. Living donor liver transplantation (LDLT) is now commonly performed for adults and children from a related or unrelated donor. Depending on the graft size needed for the recipient, either the right lobe, left lobe or the left lateral segment can be used for LDLT. In addition to addressing the problem of donor organ scarcity, LDLT allows the procedure to be scheduled electively before the recipient’s condition deteriorates or serious complications develop. LDLT also shortens the preservation time for the donor liver and decreases disease transmission from donor to recipient.

Note:

Management of acute rejection of liver transplant using either intravenous immunoglobulin (IVIg) or plasmapheresis is discussed separately in policy Nos. 8.01.05 and 8.02.02, respectively. In addition, the role of chemoembolization or radiofrequency ablation as a bridge to transplant in patients with hepatocellular cancer is addressed separately in policy Nos. 8.01.11 and 7.01.91, respectively.

 


Policy

A liver transplant, using a cadaver or living donor, is medically necessary for carefully selected patients with end-stage liver failure due to irreversibly damaged livers.

Etiologies of end-stage liver disease include, but are not limited to, the following:

A. Hepatocellular diseases

  • Alcoholic cirrhosis
  • Viral hepatitis (either A, B, C, or non-A, non-B)
  • Autoimmune hepatitis
  • Alpha-1 antitrypsin deficiency
  • Hemochromatosis
  • Protoporphyria
  • Wilson`s disease

B. Cholestatic liver diseases

  • Primary biliary cirrhosis
  • Primary sclerosing cholangitis with development of secondary biliary cirrhosis
  • Biliary atresia

C. Vascular disease

  • Budd-Chiari syndrome

D. Primary hepatocellular carcinoma

E. Inborn errors of metabolism

F. Trauma and toxic reactions

G. Miscellaneous

  • Polycystic disease of the liver
  • Familial amyloid polyneuropathy

Liver transplantation is considered investigational in the following patients:

  • Patients with an extrahepatic malignancy including cholangiocarcinoma
  • Patients with neuroendocrine tumors metastatic to the liver

Liver transplantation is considered not medically necessary in the following patients:

  • Patients with hepatocellular carcinoma that has extended beyond the liver
  • Patients with ongoing alcohol and/or drug abuse. (Evidence for abstinence may vary among liver transplant programs, but generally a minimum of 3 months is required.)

 


Policy Guidelines

General

Potential contraindications subject to the judgment of the transplant center:

  1. Known current malignancy, including metastatic cancer
  2. Recent malignancy with high risk of recurrence
  3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
  4. Other irreversible end-stage disease not attributed to liver disease
  5. History of cancer with a moderate risk of recurrence
  6. Systemic disease that could be exacerbated by immunosuppression
  7. Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Liver Specific

The MELD and PELD scores range from 6 (less ill) to 40 (gravely ill). The MELD and PELD scores will change during the course of a patient's tenure on the waiting list.

Patients with liver disease related to alcohol or drug abuse must be actively involved in a substance abuse treatment program.

Patients with polycystic disease of the liver do not develop liver failure but may require transplantation due to the anatomic complications of a hugely enlarged liver. The MELD/PELD score may not apply to these cases. One of the following complications should be present:

  • Enlargement of liver impinging on respiratory function
  • Extremely painful enlargement of liver
  • Enlargement of liver significantly compressing and interfering with function of other abdominal organs

Patients with familial amyloid polyneuropathy do not experience liver disease, per se, but develop polyneuropathy and cardiac amyloidosis due to the production of a variant transthyretin molecule by the liver. MELD/PELD exception criteria and scores may apply to these cases. Candidacy for liver transplant is an individual consideration based on the morbidity of the polyneuropathy. Many patients may not be candidates for liver transplant alone due to coexisting cardiac disease.

Patients with hepatocellular carcinoma are appropriate candidates for liver transplant only if the disease remains confined to the liver. Therefore, the patient should be periodically monitored while on the waiting list, and if metastatic disease develops, the patient should be removed from the transplant waiting list. In addition, at the time of transplant, a backup candidate should be scheduled. If locally extensive or metastatic cancer is discovered at the time of exploration prior to hepatectomy, the transplant should be aborted, and the backup candidate scheduled for transplant.

Donor Criteria – Living Donor Liver Transplant

Donor morbidity and mortality are prime concerns in donors undergoing right lobe, left lobe, or left lateral segment donor partial hepatectomy as part of living-donor liver transplantation. Partial hepatectomy is a technically demanding surgery, the success of which may be related to the availability of an experienced surgical team. In 2000, the American Society of Transplant Surgeons proposed the following guidelines for living donors:

  • Should be healthy individuals who are carefully evaluated and approved by a multidisciplinary team including hepatologists and surgeons to assure that they can tolerate the procedure
  • Should undergo evaluation to assure that they fully understand the procedure and associated risks
  • Should be of legal age and have sufficient intellectual ability to understand the procedures and give informed consent
  • Should be emotionally related to the recipients
  • Must be excluded if the donor is felt or known to be coerced
  • Needs to have the ability and willingness to comply with long-term follow-up

Cholangiocarcinoma

(Available online at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf)

According to the OPTN policy on liver allocation, candidates with cholangiocarcinoma (CCA) meeting the following criteria will be eligible for a MELD/PELD exception with a 10% mortality equivalent increase every 3 months:

  • Centers must submit a written protocol for patient care to the OPTN/UNOS Liver and Intestinal Organ Transplantation Committee before requesting a MELD score exception for a candidate with CCA. This protocol should include selection criteria, administration of neoadjuvant therapy before transplantation, and operative staging to exclude patients with regional hepatic lymph node metastases, intrahepatic metastases, and/or extrahepatic disease. The protocol should include data collection as deemed necessary by the OPTN/UNOS Liver and Intestinal Organ Transplantation Committee.
  • Candidates must satisfy diagnostic criteria for hilar CCA: malignant-appearing stricture on cholangiography and one of the following: carbohydrate antigen 19-9 100 U/mL, or and biopsy or cytology results demonstrating malignancy, or aneuploidy. The tumor should be considered unresectable on the basis of technical considerations or underlying liver disease (e.g., primary sclerosing cholangitis).
  • If cross-sectional imaging studies (computed tomography [CT] scan, ultrasound, magnetic resonance imaging [MRI]) demonstrate a mass, the mass should be 3 cm or less.
  • Intra- and extrahepatic metastases should be excluded by cross-sectional imaging studies of the chest and abdomen at the time of initial exception and every 3 months before score increases.
  • Regional hepatic lymph node involvement and peritoneal metastases should be assessed by operative staging after completion of neoadjuvant therapy and before liver transplantation. Endoscopic ultrasound-guided aspiration of regional hepatic lymph nodes may be advisable to exclude patients with obvious metastases before neoadjuvant therapy is initiated.
  • Transperitoneal aspiration or biopsy of the primary tumor (either by endoscopic ultrasound, operative, or percutaneous approaches) should be avoided because of the high risk of tumor seeding associated with these procedures.

 


Benefit Application

BlueCard/National Account Issues

Liver transplants should be considered for coverage under the transplant benefit.

What is covered under the scope of the human organ transplant (HOT) benefit needs to be considered. Typically, the following are covered under the HOT benefit:

  • hospitalization of the recipient for medically recognized transplants from a donor to a transplant recipient;
  • pre-hospital workup and hospitalization of a living donor undergoing a partial hepatectomy should be considered as part of the recipient transplant costs;
  • evaluation tests requiring hospitalization to determine the suitability of both potential and actual donors, when such tests cannot be safely and effectively performed on an outpatient basis;
  • hospital room, board, and general nursing in semi-private rooms;
  • special care units, such as coronary and intensive care;
  • hospital ancillary services;
  • physicians’ services for surgery, technical assistance, administration of anesthetics, and medical care;
  • acquisition, preparation, transportation, and storage of organ;
  • diagnostic services;
  • drugs that require a prescription by federal law.

Expenses incurred in the evaluation and procurement of organs and tissues are benefits when billed by the hospital. Included in these expenses may be specific charges for participation with registries for organ procurement, operating rooms, supplies, use of hospital equipment, and transportation of the tissue or organ to be evaluated.

Administration of products with a specific transplant benefit needs to be defined as to:

  • when the benefit begins (at the time of admission for the transplant or once the patient is determined eligible for a transplant, which may include tests or office visits prior to transplant);
  • when the benefit ends (at the time of discharge from the hospital or at the end of required follow-up, including the immunosuppressive drugs administered on an outpatient basis).

Coverage usually is not provided for:

  • HOT services, for which the cost is covered/funded by governmental, foundation, or charitable grants;
  • organs sold rather than donated to the recipient;
  • an artificial organ.


Rationale

This policy was originally created in 1995 and was regularly updated with searches of the MEDLINE database. The most recent literature search was performed for the period of July 2011 through December 2012. The following is a summary of the key findings to date.

Relevant outcomes for studies on liver transplantation include waiting time duration, dropout rates, survival time, and recurrence. As experience with liver transplant has matured, patient selection criteria have broadened to include a wide variety of etiologies. The most controversial etiologies include viral hepatitis and primary hepatocellular cancer. In particular, the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) have been controversial indications for liver transplantation because of the high potential for recurrence of the virus and subsequent recurrence of liver disease. However, registry data indicate a long-term survival rate (7 years) of 47% in HBV-positive transplant recipients, which is lower than that seen in other primary liver diseases such as primary biliary cirrhosis (71%) or alcoholic liver disease (57%). (3) Recurrence of HCV infection in transplant recipients has been nearly universal, and 10-20% of patients will develop cirrhosis within 5 years. (4) Although these statistics raise questions about the most appropriate use of a scarce resource (donor livers), the long-term survival rates isare significant in a group of patients who have no other treatment options. Similarly, the long-term outcome in patients with primary hepatocellular malignancies was poor (19%) in the past compared to the overall survival of liver transplant recipients. However, recent use of standardized patient selection criteria, such as the Milan criteria (a solitary tumor with a maximum tumor diameter of 5 cm or less, or up to 3 tumors 3 cm or smaller and without extrahepatic spread or macrovascular invasion), has dramatically improved overall survival rates. In a systematic review of liver transplant for hepatocellular carcinoma (HCC) in 2012, Maggs et al. found 5-year overall survival rates ranged from 65-94.7% in reported studies. (5) Nevertheless, transplant represents the only curative approach for many of these patients who present with unresectable organ-confined disease, and expansion of patient selection criteria, bridging to transplant or downstaging of disease to qualify for liver transplantation is currently frequently studied. Liver transplant cannot be considered curative in patients with locally extensive or metastatic liver cancer or in patients with isolated liver metastases with extrahepatic primaries or in cholangiocarcinoma. (3)

Due to the scarcity of donor organs and the success of living donation, living-donor liver transplantation has become accepted practice. The living donor undergoes hepatectomy of the right lobe, the left lobe, or the left lateral segment, which is then transplanted into the recipient. Since hepatectomy involves the resection of up to 70% of the total volume of the donor liver, the safety of the donor has been the major concern. For example, the surgical literature suggests that right hepatectomy of diseased or injured livers is associated with mortality rates of about 5%. However, initial reports suggest that right hepatectomy in healthy donors has a lower morbidity and mortality. The Medical College of Virginia reported the results of their first 40 adult-to-adult living-donor liver transplantations, performed between June 1998 and October 1999. (6) There were an equal number of related and unrelated donors. Minor complications occurred in 7 donors. The outcomes among recipients were similar to those associated with cadaveric donor livers performed during the same period of time. However, in the initial series of 20 patients, 4 of the 5 deaths occurred in recipients who were classified as 2A (see Description section). In the subsequent 20 patients, recipients classified as 2A were not considered candidates for living-donor transplant. Other case series have reported similar success rates. (7-9) Reports of several donor deaths re-emphasize the importance of careful patient selection based in part on a comprehensive consent process and an experienced surgical team. (10-12) In December 2000, the National Institutes of Health (NIH) convened a workshop focusing on living-donor liver transplantation. A summary of this workshop was published in 2002. (13) According to this document, the risk of mortality to the donor undergoing right hepatectomy was estimated to be approximately 0.2–0.5%. Based on survey results, the workshop reported that donor morbidity was common; 7% required re-exploration, 10% had to be re-hospitalized, and biliary tract complications occurred in 7%. The median complication rate reported by responding transplant centers was 21%.

Due to the potential morbidity and mortality experienced by the donor, the workshop also noted that donor consent for hepatectomy must be voluntary and free of coercion; therefore, it was preferable that the donor have a significant long-term and established relationship with the recipient. According to the workshop summary, “At the present time, nearly all centers strive to identify donors who are entirely healthy and at minimal risk during right hepatectomy. As a result, only approximately one third of persons originally interested in becoming a living liver donor complete the evaluation process and are accepted as candidates for this procedure.”

Criteria for a recipient of a living-related liver are also controversial, with some groups advocating that living-related donor livers be only used in those most critically ill; while others state that the risk to the donor is unacceptable in critically ill recipients due to the increased risk of postoperative mortality of the recipient. According to this line of thought, living-related livers are best used in stable recipients who have a higher likelihood of achieving long-term survival. (13)

In 2000, the American Society of Transplant Surgeons issued the following statement (14):

“Living donor transplantation in children has proven to be safe and effective for both donors and recipients and has helped to make death on the waiting list a less common event. Since its introduction in 1990, many of the technical and ethical issues have been addressed and the procedure is generally applied.

The development of left or right hepatectomy for adult-to-adult living donor liver transplantation has been slower. Because of the ongoing shortage of cadaver livers suitable for transplantation, adult-to-adult living donor liver transplantation has been undertaken at a number of centers. While early results appear encouraging, sufficient data are not available to ascertain donor morbidity and mortality rates. There is general consensus that the health and safety of the donor is and must remain central to living organ donation.”

Brown and colleagues reported on the results of a survey focusing on adult living-related recipients in the United States. (15) The following statistics were reported:

  • The survey encompasses 449 adult-to-adult transplantations.
  • Half of the responding programs already had performed at least one adult-to-adult living-donor liver transplantation, and 32 of the remaining 41 centers were planning to initiate such surgery.
  • 14 centers had performed more than 10 such transplantations, and these centers accounted for 80% of these transplants.
  • A total of 45% of those evaluated for living donation subsequently donated a liver lobe; 99% were genetically or emotionally related to the recipient.
  • Complications in the donor were more frequent in the centers that performed the fewest living- related donor transplantations.
  • There was 1 death among the donors, but complications were relatively common, i.e., biliary complications in 6% and reoperation in 4.5%.

In 2002, NIH sponsored a conference on living-donor liver transplantation. (10) This report offered the following observations:

  • The incidence and type of complications encountered and mortality associated with living-donor liver transplant in both donors and recipients need to be determined and compared with those for patients undergoing cadaveric transplantation.
  • The question of whether all U.S. transplant programs should perform this operation or this complex procedure should be limited to only a few select centers needs to be addressed.

HIV-Positive Patients

This subgroup of recipients has long been controversial, due to the long-term prognosis for human immunodeficiency virus (HIV) positivity, the impact of immunosuppression on HIV disease, and the interactions of immunosuppressive therapy with antiretroviral therapy in the setting of a transplanted liver. For example, most antiretroviral agents are metabolized through the liver and can cause varying degrees of hepatotoxicity. HIV candidates for liver transplantation are frequently co-infected with hepatitis B or C, and viral co-infection can further exacerbate drug-related hepatotoxicities. Nevertheless, HIV positivity is not an absolute contraindication to liver transplant due to the advent of highly active antiretroviral therapy (HAART), which has markedly changed the natural history of the disease and the increasing experience with liver transplant in HIV-positive patients. Furthermore, the United Network of Organ Sharing (UNOS) states that asymptomatic HIV-positive patients should not necessarily be excluded for candidacy for organ transplantation, stating “A potential candidate for organ transplantation whose test for HIV is positive but who is in an asymptomatic state should not necessarily be excluded from candidacy for organ transplantation, but should be advised that he or she may be at increased risk of morbidity and mortality because of immunosuppressive therapy.” (16) In 2001, the Clinical Practice Committee of the American Society of Transplantation proposed that the presence of AIDS [acquired immune deficiency syndrome] could be considered a contraindication to kidney transplant unless the following criteria were present. (17) These criteria may be extrapolated to other organs:

  • CD4 count >200 cells/mm-3 for >6 months
  • HIV-1 RNA undetectable
  • On stable anti-retroviral therapy >3 months
  • No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioses mycosis, resistant fungal infections, Kaposi’s sarcoma, or other neoplasm).
  • Meeting all other criteria for transplantation.

It is likely that each individual transplant center will have explicit patient selection criteria for HIV-positive patients.

In 2011, Cooper and colleagues conducted a systematic review to evaluate liver transplantation in patients co-infected with HIV and hepatitis. (18) The review included 15 cohort studies and 49 case series with individual patient data. The survival rate of patients was 84.4% (95% confidence interval [CI]: 81.1-87.8%) at 12 months. Patients were 2.89 (95% CI: 1.41-5.91) times more likely to survive when HIV viral load at the time of transplantation was undetectable compared to those with detectable HIV viremia.

Terrault and colleagues reported on a prospective, multicenter study to compare liver transplantation outcomes in 3 groups: patients with both HCV and HIV (n=89), patients with only HCV (n=235), and all transplant patients age 65 or older. (19) Patient and graft survival reductions were significantly associated with only one factor: HIV infection. At 3 years, in the HCV only group, patient and graft survival rates were significantly better at 79% (95% CI:72-84%) and 74% (95% CI: 66-79%), respectively, than the group with both HIV and HCV infection at 60% (95% CI: 47-71%) and 53% (95% CI: 40-64%). While HIV infection reduced 3-year survival rates after liver transplantation in patients also infected with HCV, there were still a majority of patients experiencing long-term survival.

Hepatocellular Carcinoma

Interest in expanding liver transplant selection criteria for hepatocellular carcinoma (HCC) and other indications is ongoing. Patient selection questions have focused mainly on the number and size of tumors. An editorial by Llovet (18) noted that the Milan criteria, which specify that patients may either have a solitary tumor with a maximum tumor diameter of 5 cm or less, or up to 3 tumors 3 cm or smaller are considered the gold standard. A 2001 paper from the University of California, San Francisco (UCSF), (20) proposed expanded criteria to include patients with a single tumor up to 6.5 cm in diameter, 3 or fewer tumors with maximum size 4.5 cm, and a total tumor size of 8 cm or less. It should be noted that either set of criteria can be applied preoperatively (with imaging) or with pathology of the explanted liver at the time of intended transplant. Preoperative staging often underestimates what is seen on surgical pathology. To apply pathologic criteria, a backup candidate must be available in case preoperative staging is inaccurate. Given donor organ scarcity, any expansion of liver transplant selection criteria has the potential to prolong waiting times for all candidates. Important outcomes in assessing expanded criteria include waiting time duration, death, or deselection due to disease progression while waiting (dropout), survival time, and time to recurrence (or related outcomes such as disease-free survival). Survival time can be estimated beginning when the patient is placed on the waiting list, using the intention-to-treat principal, or at the time of transplantation. Llovet stated that 1-year dropout rates for patients meeting Milan criteria are 15–30%, and 5-year survival rates not reported by intention-to-treat should be adjusted down by 10–15%.

A limited body of evidence is available for outcomes among patients exceeding Milan criteria but meeting UCSF criteria (see following table). The largest series was conducted in 14 centers in France, (21) including an intention-to-treat total of 44 patients based on preoperative imaging at the time of listing and a subset of 39 patients meeting pathologic UCSF criteria. The median waiting time was 4.5 months, shorter than the typical 6–12 months in North America. Dropouts comprised 11.4% of total. Post-transplant overall patient 5-year survival, at 63.6%, was more favorable than the intention-to-treat probability (45.5%) but less favorable than among larger numbers of patients meeting Milan criteria. Similar findings were seen for disease-free survival and cumulative incidence of recurrence. Three centers in Massachusetts (22) included 10 patients beyond pathologic Milan criteria but within UCSF criteria. Two-year survival post-transplant was 77.1%, with 2 patients dying and 8 alive after a median of 32 months. A group of 74 patients meeting preoperative Milan criteria had a 2-year survival probability of about 73%, but it is inadvisable to compare different preoperative and pathologic staging criteria. From the series of patients who developed the expanded UCSF criteria, (23) 14 satisfied those criteria on pathology but exceeded the Milan criteria. UCSF investigators did not provide survival duration data for this subgroup, but noted that 2 patients died. A center in Essen, Germany reported on 4 patients. Although the French series suggests that outcomes among patients exceeding Milan criteria and meeting UCSF criteria are worse than for patients meeting Milan criteria, it is unclear whether the latter group still achieves acceptable results. A benchmark of 50% 5-year survival has been established in the liver transplant community, (20) and the French study meets this by post-transplant pathologic staging results (63.6%) and falls short by preoperative intention-to-treat results (45.5%).

In their 2008 review, Schwartz and colleagues argue that selection based exclusively on the Milan criteria risks prognostic inaccuracy due to the diagnostic limitations of imaging procedures and the surrogate nature of size and number of tumors. (24) They predict that evolution of allocation policy will involve the following: 1. the development of a reliable prognostic staging system to help with allocation of therapeutic alternatives; 2. new molecular markers that might improve prognostic accuracy; 3. aggressive multimodality neoadjuvant therapy to downstage and limit tumor progression before transplant and possibly provide information about tumor biology based on response to therapy; and, 4. prioritization for transplantation should consider response to neoadjuvant therapy, time on waiting list, suitability of alternative donor sources. Two papers describe work on identifying predictors of survival and recurrence of disease. Ioannou and colleagues analyzed UNOS data pre- and post-adoption of the Model for End-stage Liver Disease (MELD) allocation system finding a 6-fold increase in recipients with HCC and that survival in the MELD era was similar to survival in patients without HCC. (25) The subgroup of patients with larger (3-5 cm) tumors, serum alpha-fetoprotein level equal to or greater than 455 mg/mL, or a MELD score equal to or greater than 20, however, had poor transplantation survival. A predicting cancer recurrence scoring system was developed by Chan et al. based on a retrospective review and analysis of liver transplants at 2 centers to determine factors associated with recurrence of HCC. (26) Of 116 patients with findings of HCC in their explanted livers, 12 developed recurrent HCC. Four independent significant explant factors were identified by stepwise logistic regression: size of 1 tumor greater than 4.5 cm, macroinvasion, and bilobar tumor were positive predictors of recurrence, and the presence of only well-differentiated HCC was a negative predictor. Points were assigned to each factor in relation to its odds ratio. The accuracy of the method was confirmed in 2 validation cohorts.

In 2010, Guiteau and colleagues reported on 445 patients transplanted for HCC in a multicenter, prospective study in UNOS Region 4. (27) On preoperative imaging, 363 patients met Milan criteria, and 82 patients were under expanded Milan criteria consisting of 1 lesion less than 6 cm, equal to or less than 3 lesions, none greater than 5 cm and total diameter less than 9 cm. Patient allograft and recurrence-free survival at 3 years did not differ significantly between patients meeting Milan criteria versus patients under the expanded criteria (72.9% and 77.1%, 71% and 70.2% and 90.5% and 86.9%, all respectively). While preliminary results showed similar outcomes when using expanded Milan criteria, the authors noted their results were influenced by waiting times in Region 4 and that similar outcomes may be different in other regions with different waiting times. Additionally, the authors noted that an HCC consensus conference report does not recommend expanding Milan criteria nationally and encourages regional agreement. (28)

In a 2012 meta-analysis, Li and colleagues compared primary liver transplantation to salvage liver transplantation (liver transplantation after liver resection) for HCC. (29) Included in the meta-analysis were 11 case-controlled or cohort studies totaling 872 primary liver transplants and 141 salvage liver transplants. Survival rates of patients who exceeded the Milan criteria at 1, 3, and 5 years were not significantly different between the 2 groups (1-year odds ratio [OR]: 0.26, 95% CI: 0.01-4.94, p=0.37; 3-year OR: 0.41, 95% CI: 0.01-24.54, p=0.67; and 5-year OR: 0.55, 95% CI: 0.07-4.48, p=0.57).

Overall, the evidence base is insufficient to permit conclusions about health outcomes after liver transplantation among patients exceeding Milan criteria and meeting expanded UCSF or other criteria.

Outcomes Among Patients with Hepatocellular Carcinoma Exceeding Milan Selection Criteria and Meeting UCSF Criteria

 

Outcomes Among Patients with Hepatocellular Carcinoma Exceeding Milan Selection Criteria and Meeting UCSF Criteria 
Study  Outcome  Group  Probability (%) 
1yr  2yr  5yr 
Decaens et al., 2006 (17) 14 centers in France, Meeting Milan criteria (Milan+). Exceeding Milan criteria, meeting UCSF criteria (Milan-/UCSF+)   Intention-to-treat, preoperative  
Overall patient survival  Milan+  279          60.1 
Milan-/UCSF+  44          45.5 
Cumulative incidence of recurrence  Milan+              20.2 
Milan-/UCSF+              27.1 
Disease-free survival  Milan+              60.4 
Milan-/UCSF+              47.8 
Post-transplant, pathologic (p)  
Overall patient survival  pMilan+  184          70.4 
pMilan-/pUCSF+  39          63.6 
Cumulative incidence of recurrence  pMilan+              9.4 
pMilan-/pUCSF+              16.5 
Disease-free survival  pMilan+              7.02 
pMilan-/pUCSF+              62.7 
Milan-/UCSF+ median waiting time 4.5 mo (0.1-20.4); 5/44 dropouts (11.4%)  
Leung et al., 2004 (18) 3 centers in Massachusetts, Meeting preoperative Milan criteria (Milan+)  Post-transplant overall patient survival  Milan+  74  85.9  ~73  50.9 
pMilan-/pUCSF+  10      77.1     
2 patients died at 3 and 22 months, 8 patients alive after median 32 mo follow-up (6.6-73.5)  
Yao et al., 2002 (19) University of California, San Francisco  Post-transplant overall patient survival  pMilan+  46  91  81  72 
pMilan-/pUCSF+, n=14, 2 patients died, 8 alive but no information on survival duration, 1 patient retransplanted 5 mo after initial transplant  
Sotiropoulos et al., 2006 (25) Essen, Germany. Unclear if criteria preoperative or pathologic.  Milan-/UCSF+, n=4, 1 patient died at 20 mo, 3 patients alive at median follow-up 57 mo.  

 

Cholangiocarcinoma

Reports on outcomes after liver transplantation for cholangiocarcinoma, or bile duct carcinoma generally distinguish between intrahepatic and extrahepatic tumors, the latter including hilar or perihilar tumors. Recent efforts have focused on pretransplant downstaging of disease with neoadjuvant radiochemotherapy.

In 2012, Gu and colleagues reported on a systematic review and meta-analysis of 14 clinical trials on liver transplantation for cholangiocarcinoma. (31) Overall 1-, 3-, and 5-year pooled survival rates from 605 study patients were 0.73 (95% CI: 0.65-0.80), 0.42 (95% CI: 0.33-0.51), and 0.39 (95% CI: 0.28-0.51), respectively. When patients received adjuvant therapies preoperatively, 1-, 3-, and 5-year pooled survival rates improved and were 0.83 (95% CI: 0.57-0.98), 0.57 (95% CI: 0.18-0.92), and 0.65 (95% CI: 0.40-0.87), respectively.

In 2012, Darwish Murad et al. reported on 287 patients from 12 transplant centers treated with neoadjuvant therapy for perihilar cholangiocarcinoma followed by liver transplantation. (32) Intent-to-treat survival (after a loss of 71 patients before liver transplantation) was 68% at 2 years and 53% at 5 years, and recurrence-free survival rates post-transplant were 78% at 2 years and 65% at 5 years. Survival time was significantly shorter for patients who had a previous malignancy or did not meet UNOS criteria by having a tumor size greater than 3 cm, metastatic disease, or transperitoneal tumor biopsy. (p<0.001).

The European Liver Transplant Registry was cited by a review article. (33) Among 186 patients with intrahepatic cholangiocarcinoma, 1-year survival was 58%, and 5-year survival was 29%. In 169 patients with extrahepatic cholangiocarcinoma, the probabilities were 63% and 29%, respectively. The Cincinnati Transplant Registry (34) reported on 207 patients with either intrahepatic or extrahepatic cholangiocarcinoma, finding a 1-year survival of 72% and a 5-year rate of 23%. The multicenter Spanish report (35) included 36 patients with hilar tumors and 23 with peripheral intrahepatic disease. One-year survival was 82% and 77%, while 5-year survival was 30% and 23% in the 2 groups, respectively.

Among the individual centers, the Mayo Clinic in Minnesota has the most experience and most favorable results (36, 37). Between 1993 and 2006, 65 patients underwent liver transplantation for unresectable perihilar cholangiocarcinoma or had perihilar tumor due to primary sclerosing cholangitis. Unresectable patients underwent neoadjuvant radiochemotherapy. One-year survival was 91% and 5-year survival was 76%. The University of California, Los Angeles (UCLA)/Cedars-Sinai, (38) reported on 25 cases of both intrahepatic and extrahepatic cholangiocarcinoma. One-year survival was 71% and 3-year survival was 35%. The University of Pittsburgh found 1-year survival of 70% and 5-year survival of 18% among 20 patients with intrahepatic cholangiocarcinoma. (39) A German study of 24 patients reported the poorest results. (40) In 2011, Friman and colleagues reported on 53 patients who received liver transplants for cholangiocarcinoma during the period of 1984-2005, in Norway, Sweden, and Finland. (41) The 5-year survival rate was 25% overall, 36% in patients with TNM stage equal to or less than 2, and 10% in patients with TNM greater than 2. Upon further analysis using only data from those patients transplanted after 1995, the 5-year survival rate increased to 38% versus 0% for those transplanted before 1995. Additionally, the 5-year survival rate increased to 58% in those patients transplanted after 1995 with TNM stage equal to or less than 2 and a CA 19-9 equal to or less than 100. The authors suggest transplantation may have acceptable outcomes in select patients.

Outcomes Among Patients with Cholangiocarcinoma

 

Outcomes Among Patients with Cholangioarcinoma

Study

Outcome

Group

n

Probability (%)

1yr

2yr

3yr

5yr

Pascher et al. 2003 (review, 26) European Liver Transplant Registry

Overall patient survival

IH-CCA

186

58

 

38

29

EH-CCA

169

63

 

38

29

Meyer et al. 2000 (27) Cincinnati Transplant Registry unresectable CCA, cholangiohepatoma, incidental median follow-up 23 mo (

Overall patient survival

IH/EH-CCA

207

72

48

 

23

Robles et al. 2004 (28) Multiple Centers in Spain 03/88-09/01; hilar or peripheral CCA; unresectable, postoperative recurrent, or incidental

Overall patient survival

Hilar CCA

36

82

 

53

30

Peripheral CCA

23

77

 

65

23

Crude recurrence rate: EH-CCA: 19/36 (53%); IH-CCA: 8/23 (35%)

Heimbach et al. 2006 (29); Rea et al. 2006 (31) Mayo Clinic, Rochester MN, USA 01/93-01/06, aggressive neoadjuvant radiochemotherapy, unresectable perihilar CCA or perihilar CCA from primary sclerosing cholangitis mean follow-up 32 mo (2 d – 13 yr)

Overall patient survival

Perihilar CCA

65

91

 

 

76

Cumulative recurrence

 

38

0

 

5

13

Crude recurrence rate: 11/65 (17%) median onset 22 mo (7-65)

Shimoda et al. 2001 (31) UCLA/Cedars-Sinai, Los Angeles, CA, USA 1984-2000; IH or EH CCA median follow-up 22.3 mo

Overall patient survival

All

25

71

 

35

 

IH-CCA

16

62

 

39

 

EH-CCA

9

86

 

31

 

Disease-free survival

All

25

67

 

42

 

IH-CCA

16

70

 

35

 

EH-CCA

9

57

 

57

 

Casavilla et al., 1997 (32) University of Pittsburgh, PA, USA 1981-1994

Overall patient survival

IH-CCA

20

70

 

29

18

Tumor-free survival

 

20

67

 

31

31

Weimann et al. 2000 (33) Hannover, GER 07/78-12/96; unresectable CCA

Overall patient survival

IH-CCA

24

21

8

4

0

Crude recurrence rate: 15/24 (63%)

Friman et al. 2011 (34)

Norway, Sweden, and Finland 1984-2005; Inresectable CCA

Actual patient survival

All

53

 

 

 

25

 

TNM stage > 2

21

 

 

 

10

 

TNM stage ≤ 2

32

 

 

 

36

 

CCA: cholangiocarcinoma; EH: extrahepatic; IH: intrahepatic

Some articles have reported recurrence data using survival analysis techniques. In a series of 38 patients from the Mayo Clinic, cumulative recurrence was 0% at 1 year, 5% at 3 years, and 13% at 5 years. (37) The series of 20 patients from the University of Pittsburgh experienced 67% 1-year tumor-free survival and a 31% 5-year rate. (38) The multicenter Spanish series reported crude recurrence rates of 53% and 36% for extrahepatic and intrahepatic cholangiocarcinoma, respectively. (35) The German center at Hannover found a crude recurrence rate of 63%. (40)

Mayo Clinic has reported promising results after liver transplantation for cholangiocarcinoma. Five-year patient survival among 65 patients who received neoadjuvant radiochemotherapy was 76%. No other center or group of centers reported 5-year survival above 30%. The Mayo Clinic found a 5-year cumulative recurrence rate of 13% among 38 patients and additional recurrence data are quite limited. While a single center’s results are encouraging, it is important to see if other centers can produce similar findings before forming conclusions about outcomes after liver transplantation for cholangiocarcinoma.

In a 2008 review, Heimbach considers the published outcomes of the combined protocol in the context of data on outcomes for surgical resection and concludes that outcomes of neoadjuvant chemoradiotherapy with subsequent liver transplantation for patients with early-stage hilar cholangiocarcinoma, which is unresectable, or arising in the setting of primary sclerosing cholangitis are comparable to transplantation for patients with HCC and other chronic liver diseases and superior to resection. (42) The author describes intraoperative challenges attributable to the neoadjuvant therapy including severe inflammatory changes and dense fibrosis and suggests that key principles to be considered by centers considering use of the combined protocol include a multidisciplinary approach, pretransplant staging, inclusion of only patients without lymph node metastasis, replacement of irradiated vessels (when possible), and monitoring for postoperative vascular complications. Wu et al. describe an extensive surgical procedure combined with radiotherapy. (43) They retrospectively review their experience with surveillance and early detection of cholangiocarcinoma and en bloc total hepatectomy-pancreaticoduodenectomy-orthotopic liver transplantation (OLT-Whipple) in a small series of patients with early-stage cholangiocarcinoma complicating primary sclerosing cholangitis. Surveillance involved endoscopic ultrasound and endoscopic retrograde cholangiopancreatography and cytological evaluation. Patients diagnosed with cholangiocarcinoma were treated with combined extra-beam radiotherapy, lesion-focused brachytherapy, and OLT-Whipple. Cholangiocarcinoma was detected in 8 of the 42 patients followed up according to the surveillance protocol between 1988 and 2001, and 6 patients underwent OLT-Whipple. One died at 55 months after transplant of an unrelated cause without tumor recurrence, and 5 are without recurrence at 5.7–10.1 years.

Hepatitis C

Mukherjee and Sorrell, reviewing controversies in liver transplantation for hepatitis C, indicate that the greatest opportunity for HCV eradication is pretransplant before hepatic decompensation. (44) Challenges of treatment post-transplantation include immunosuppressive drugs and abnormal hematologic, infectious, and liver function parameters. The authors list the following factors associated with poor outcomes in liver transplantation for recurrent HCV: high HCV-RNA level pretransplant, non-Caucasian ethnicity, advanced donor age, T cell-depleting therapies, inappropriate treatment of Banff A1 acute cellular rejection (ACR) with steroid boluses, cytomegalovirus disease, and year of transplantation (worse with recent transplants). They cite the International Liver Transplantation Society Consensus on Retransplantation, which states that the following are associated with worse outcomes of retransplantation: total bilirubin level >10mg/dL, creatinine level >2 mg/dL, age >55 years, development of cirrhosis in the first post-transplant year, and donor age >40 years.

As noted above, Terrault and colleagues reported on a prospective, multicenter study to compare liver transplantation outcomes in 3 groups: patients with both HIV and HCV infection (n=89), patients with only HCV (n=235), and all transplant patients age 65 and older. (19) HCV status was not significantly associated with reduced patient and graft survival. In the HCV-only group, patient and graft survival rates were significantly better at 79% (95% CI: 72-84%) and 74% (95% CI: 66-79%), respectively, than the group with HIV and HCV at 60% (95% CI: 47-71%) and 53% (95% CI: 40-64%). While HIV infection reduced 3-year survival rates after liver transplantation in patients also infected with HCV, there were still a majority of patients experiencing long-term survival.

Metastatic Neuroendocrine Tumors

Neuroendocrine tumors (NETs) are relatively rare neoplasms that are generally slow-growing but rarely cured when metastatic to the liver. Treatment options to control or downstage the disease include chemotherapy and debulking procedures, including hepatic resection. In select patients with non-resectable, hormonally active liver metastases refractory to medical therapy, liver transplantation has been considered as an option to extend survival and minimize endocrine symptoms. In 2011, Mathe and colleagues conducted a systematic review of the literature to evaluate patient survival after liver transplant for pancreatic NETs. (45) Data from 89 transplanted patients from 20 clinical studies were included in the review. Sixty-nine patients had primary endocrine pancreatic tumors, 9 patients were carcinoids, and 11 patients were not further classified. Survival rates at 1, 3, and 5 years were 71%, 55%, and 44%, respectively. The mean calculated survival rate was 54.45 ± 6.31 months, and the median calculated survival rate was 41 months (95% CI: 22–76 months). While there may be centers that perform liver transplantation on select patients with NETs, further studies are needed to determine appropriate selection criteria. The quality of available studies is currently limited by their retrospective nature and heterogeneous populations.

Retransplantation

In 2012, Bellido and colleagues reported on a retrospective cohort study of 68 consecutive adult liver retransplantations using registry data. (46) Survival probability using Kaplan-Meier curves with log-rank tests to compare 21 urgent versus 47 elective retransplantations were calculated. Overall survival rates were significantly better in patients undergoing urgent procedures (87%), which were mostly due to vascular complications than elective procedures (76.5%), which were mostly related to chronic rejection.

In 2011, Remiszewski et al. examined factors influencing survival outcomes in 43 liver retransplantation patients. (47) When compared to primary liver transplantation patients, retransplantation patients had significantly lower 6-year survival rates (80% vs. 58%, respectively; p=0.0001). The authors also reported low negative correlations between survival time and time from original transplantation until retransplantation and between survival time and patient age. Survival time and cold ischemia time showed a low positive correlation.

.

Hong and colleagues, in 2011, reported on a prospective study of 466 adults to identify risk factors for survival after liver retransplantation. (48) Eight risk factors were identified as predictive of graft failure, including age of recipient, MELD score greater than 27, more than 1 prior liver transplant, need for mechanical ventilation, serum albumin of less than 2.5 g/dL, donor age older than 45 years, need for more than 30 units of packed red blood cells transfused intraoperatively, and time between prior transplantation and retransplantation between 15 and 180 days. The authors propose this risk-stratification model can be highly predictive of long-term outcomes after adult liver retransplantation and can be useful in patient selection.

Ongoing Clinical Trials

A search of online site ClinicalTrials.gov in November 2012 identified many ongoing clinical trials on liver transplant. There is an ongoing multi-institutional prospective study of liver and kidney transplantation in HIV-positive recipients (NCT00074386). The target enrollment is 150 kidney transplant recipients and 125 liver transplant recipients. The goals of the trial are described as follows (20):

“Primary aims of the study are to assess the impact of iatrogenic immunosuppression on patient survival and to assess the impact of HIV infection and antiretroviral treatment on graft survival, including in the setting of HBV or HCV coinfection and HIV-associated nephropathy. Secondary aims include assessment of the effect of immunosuppressant therapy on CD 4+ cell counts, HIV RNA levels, and opportunistic complications; exploration of the relationships among disease development, the host immune response and viral evolution with regard to HBC, HCV, CMV, herpes virus-8 and HPV; assessment of the impact of HIV infection on alloimmune response and graft rejection rates; and analysis of pharmacokinetic interactions between immunosuppressant drugs and hepatically metabolized antiretroviral agents.“

The participating institutions are as follows:

Kidney and Liver

Beth Israel Deaconess Medical Center, Boston, MA

Georgetown Medical Center, Washington, DC

Mount Sinai School of Medicine, New York

University of California, San Francisco

University of Chicago

University of Cincinnati

University of Minnesota

University of Pennsylvania

University of Pittsburgh

University of Virginia

Kidney

Drexel University, Philadelphia

University of Maryland

University of Miami

Washington Hospital Center, Washington, DC

Liver

Cedars-Sinai Medical Center, Los Angeles

Columbia University, NY, NY

At Stanford University, in a Phase II study that began in January 2011, researchers will evaluate whether neoadjuvant stereotactic body radiotherapy and chemotherapy for unresectable cholangiocarcinoma can lead to successful liver transplantation (NCT01151761). Washington State University is conducting a prospective registry study of neoadjuvant chemoradiation in conjunction with liver transplantation for cholangiocarcinoma (NCT00301379). A study on liver transplantation for hilar cholangiocarcinoma began in March 2012 in Italy (NCT01549795) This study will enroll 33 patients and has a primary completion date of July 2013.

Liver transplantation for metastatic neuroendocrine tumors is being evaluated in a German study (NCT 01201096). In this observational study, patients will receive neoadjuvant peptide receptor-mediated radiotherapy with 177 lutetium about 9 months prior to liver transplantation.

A study on liver transplantation after downstaging hepatocellular carcinoma exceeding the Milan Criteria is ongoing in Italy (NCT01387503). This study is evaluating 260 patients and is expected to be completed in January 2014.

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2012

In response to requests, input was received from 3 physician specialty societies and 5 academic medical centers while this policy was under review. There was consensus of agreement by the reviewers that liver transplantation may be medically necessary for end-stage liver failure due to irreversibly damaged livers from various disease states such as those listed in the above policy statement. There was also consensus of agreement by the reviewers that liver retransplantation is appropriate in patients with acute or chronic liver failure such as primary graft non-function, ischemic type biliary injury after donation after cardiac death, hepatic artery thrombosis, chronic rejection or recurrent diseases such as primary sclerosing cholangitis (PSC), autoimmune hepatitis, and hepatitis C resulting in end-stage liver failure. There was general support for the use of liver transplantation for the treatment of cholangiocarcinoma for patients who meet strict eligibility criteria. In general, there was not support for the use of liver transplantation for neuroendocrine tumors metastatic to the liver.

Summary

Liver transplant is an accepted treatment of end-stage liver disease that provides a survival benefit in appropriately selected patients and thus, may be considered medically necessary for the above indications listed in the Policy Statement and in those otherwise meeting UNOS criteria. Liver transplantation is investigational in patients in whom the procedure is expected to be futile due to comorbid disease or in whom post-transplantation care is expected to significantly worsen comorbid conditions. Case series and case-control data indicate that HIV-infection is not an absolute contraindication to liver transplant; for patients who meet selection criteria, these studies have demonstrated patient and graft survival rates are similar to those in the general population of kidney transplant recipients.

Recent literature continues to address expanded criteria for transplantation for HCC, predictors of recurrence, the role of neoadjuvant therapy in patients with HCC, expanded donor criteria, transplantation and retransplantation for hepatitis C, and living donor transplantation. Further study is needed before liver transplant selection criteria can be expanded for HCC.

Liver transplantation for hilar cholangiocarcinoma is performed at some transplant centers, and long-term survival has been reported in select patients with unresectable disease. For metastatic neuroendocrine tumors, cure of disease is not achieved and 5-year survival is generally not high. However, there have been reports of survival benefit in patients receiving liver transplantation for unresectable neuroendocrine tumor metastasis confined to the liver. Based on survival data and clinical vetting input, transplantation in patients with hilar cholangiocarcinoma who meet strict eligibility criteria may be considered medically necessary; transplantation for neuroendocrine tumors metastatic to the liver is considered investigational.

Case series have demonstrated favorable outcomes with liver retransplantation in certain populations, such as when criteria for an original liver transplantation are met for retransplantation. While some evidence suggests outcomes after retransplantation may be less favorable than for initial transplantation in some patients, long-term survival benefits have been demonstrated. There was support from clinical vetting for retransplantation following primary graft non-function, hepatic artery thrombosis, ischemic biliary injury after donation after cardiac death (DCD), chronic rejection or certain recurrent non-neoplastic diseases resulting in end-stage liver failure in a primary transplant. As a result, retransplantation after initial failed liver transplant may be considered medically necessary in these situations.

Practice Guidelines and Position Statements

In December 2010, 10 international liver diseases or transplantation societies held an international consensus conference on liver transplantation for HCC. (49) Consensus criteria for selecting candidates for liver transplantation were developed at the conference. Milan criteria was recommended for use as the benchmark for patient selection, although it is noted the Milan criteria may be modestly expanded based on data from expansion studies that demonstrate outcomes that are comparable to outcomes from studies using the Milan criteria. Candidates for liver transplantation should also have a predicted survival of 5 years or more. The consensus criteria indicate alpha-fetoprotein concentrations may be used with imaging to assist in determining patient prognosis.

In regards to liver retransplantation, the consensus criteria issued a weak recommendation indicating retransplantation after graft failure of a living donor transplant for HCC is acceptable in patients meeting regional criteria for a deceased donor liver transplant. A strong recommendation was issued indicating liver retransplantation with a deceased donor for graft failure for patients exceeding regional criteria is not recommended. And the consensus criteria issued a strong recommendation that liver retransplantation for recurrent HCC is not appropriate. However, a de-novo HCC may be treated as a new tumor and retransplantation may be considered even though data to support this are limited.

In 2005, the American Association for the Study of Liver Diseases (AASLD) issued guidelines on evaluating patients for liver transplant. (50) These guidelines state liver transplantation is indicated for acute or chronic liver failure from any cause after all effective medical treatments have been attempted. Furthermore, the AASLD guidelines indicate patients should be assessed by a transplantation center to determine whether liver transplantation is appropriate. While the AASLD guidelines indicate liver transplant may be appropriate in patients with cholangiocarcinoma and metastatic neuroendocrine tumors, these recommendations and many of the recommendations in the AASLD guidelines are based on opinion.

The European Neuroendocrine Society (ENETS) issued consensus guidelines in 2008 for the management of patients with liver metastases from neuroendocrine tumors. (51) The ENETS guidelines indicate, in a “minimal consensus” statement, that liver transplantation may be considered for diffuse unresectable neuroendocrine tumor metastases or when hormonal disturbances that are refractory to medical therapy are life-threatening.

The National Comprehensive Cancer Network (NCCN) guidelines on hepatobiliary cancers recommends liver transplant in patients with HCC meeting UNOS criteria equal to or less than 5 cm, or 2-3 lesions equal to or less than 3 cm when there is no macrovascular involvement or extrahepatic disease. (52) In patients with Child-Pugh Class A liver function with tumors that are resectable and meet UNOS criteria, NCCN indicates resection or transplant may be considered. The NCCN guidelines on hepatobiliary cancers also indicate liver transplant is appropriate in select patients with extrahepatic cholangiocarcinoma, which is unresectable, but biliary and hepatic function is otherwise normal or when underlying chronic liver disease precludes surgery. These are level 2A recommendations based on lower-level evidence and uniform consensus.

Liver transplantation guidelines for non-alcoholic steatohepatitis (NASH) were developed by the Council of the British Transplant Society and approved by the British Society of Gastroenterology, the British Association for the Study of Liver and NHS Blood and Transplant in 2012. These guidelines indicate liver transplantation may be considered for the treatment of NASH cirrhosis with end-stage liver disease or HCC. (53) These guidelines are based primarily on consensus of expert opinion.

Medicare National Coverage

Medicare covers adult liver transplantation for end-stage liver disease and HCC when performed in a facility which is approved by the Centers for Medicare and Medicaid Services (CMS) as meeting institutional coverage criteria for liver transplants. (54) The following conditions must be met for coverage of HCC:

  • The patient is not a candidate for subtotal liver resection;
  • The patient's tumor(s) is less than or equal to 5 cm in diameter;
  • There is no macrovascular involvement; and
  • There is no identifiable extrahepatic spread of tumor to surrounding lymph nodes, lungs, abdominal organs or bone.

Beginning June 21, 2012, upon review of this National Coverage Decision for new evidence, Medicare began offering coverage for adult liver transplantation, at Medicare Administrative Contractor discretion, for extrahepatic unresectable cholangiocarcinoma, liver metastases due to a neuroendocrine tumor and hemangioendothelioma. Adult liver transplantation is excluded for other malignancies.

Pediatric liver transplantation is covered for children (younger than age 18 years) when performed in a CMS-approved pediatric hospital for extrahepatic biliary atresia or any other form of end-stage liver disease, except that coverage is not provided for children with a malignancy extending beyond the margins of the liver or those with persistent viremia.

 

References:

  1. Organ Procurement and Transplantation Network (OPTN). Organ Distribution: Allocation of Livers. 2012. Available online at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf. Last accessed November 20, 2012.
  2. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2):464-70.
  3. Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. Clin Transplants 1995:19-33.
  4. Sheiner P, Rochon C. Recurrent hepatitis C after liver transplantation. Mt Sinai J Med 2012; 79(2):190-8.
  5. Maggs JR, Suddle AR, Aluvihare V et al. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35(10):1113-34.
  6. Marcos A, Ham JM, Fisher RA et al. Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe. Liver Transplant 2000; 6(3):296-301.
  7. Wachs ME, Bak TE, Karrer FM et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation 1998; 66(10):1313-6.
  8. Fan ST, Lo CM, Liu CL et al. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000; 135(3):336-40.
  9. Inomata Y, Uemoto S, Asonuma K et al. Right lobe graft in living donor liver transplantation. Transplantation 2000; 69(2):258-64.
  10. Malago M, Testa G, Marcos A et al. Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transplant 2001; 7(10):921-7.
  11. Renz JF, Busuttil RW. Adult-to-adult living-donor liver transplantation: a critical analysis. Semin Liver Dis 2000; 20(4):411-24.
  12. Bak T, Wachs M, Trotter J et al. Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transplant 2001; 7(8):680-6.
  13. Shiffman ML, Brown RS, Jr., Olthoff KM et al. Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transplant 2002; 8(2):174-88.
  14. American Society of Transplant Surgeons' position paper on adult-to-adult living donor liver transplantation. Liver Transplant 2000; 6(6):815-7.
  15. Brown RS, Jr., Russo MW, Lai M et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348(9):818-25.
  16. United Network for Organ Sharing. Policies and Bylaws. Alexandria, VA: United Network for Organ Sharing;2004.
  17. Steinman TI, Becker BN, Frost AE et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71(9):1189-204.
  18. Cooper C, Kanters S, Klein M et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS 2011; 25(6):777-86.
  19. Terrault NA, Roland ME, Schiano T et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplant 2012; 18(6):716-26.
  20. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33(6):1394-403.
  21. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transplant 2006; 12(12):1761-9.
  22. Leung JY, Zhu AX, Gordon FD et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transplant 2004; 10(11):1343-54.
  23. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transplant 2002; 8(9):765-74.
  24. Schwartz ME, D'Amico F, Vitale A et al. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol 2008; 34(3):256-62.
  25. Ioannou GN, Perkins JD, Carithers RL, Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134(5):1342-51.
  26. Chan EY, Larson AM, Fix OK et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transplant 2008; 14(7):956-65.
  27. Guiteau JJ, Cotton RT, Washburn WK et al. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant 2010; 10(9):2092-8.
  28. Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16(3):262-78.
  29. Li HY, Wei YG, Yan LN et al. Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2012; 18(19):2415-22.
  30. Sotiropoulos GC, Molmenti EP, Omar OS et al. Liver transplantation for hepatocellular carcinoma in patients beyond the Milan but within the UCSF criteria. Eur J Med Res 2006; 11(11):467-70.
  31. Gu J, Bai J, Shi X et al. Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer 2012; 130(9):2155-63.
  32. Darwish Murad S, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143(1):88-98 e3; quiz e14.
  33. Pascher A, Jonas S, Neuhaus P. Intrahepatic cholangiocarcinoma: indication for transplantation. J Hepatobiliary Pancreat Surg 2003; 10(4):282-7.
  34. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69(8):1633-7.
  35. Robles R, Figueras J, Turrion VS et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239(2):265-71.
  36. Heimbach JK, Gores GJ, Haddock MG et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82(12):1703-7.
  37. Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242(3):451-8; discussion 58-61.
  38. Shimoda M, Farmer DG, Colquhoun SD et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transplant 2001; 7(12):1023-33.
  39. Casavilla FA, Marsh JW, Iwatsuki S et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185(5):429-36.
  40. Weimann A, Varnholt H, Schlitt HJ et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000; 87(9):1182-7.
  41. Friman S, Foss A, Isoniemi H et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 2011; 46(3):370-5.
  42. Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin Gastroenterol 2008; 24(3):384-8.
  43. Wu Y, Johlin FC, Rayhill SC et al. Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transplant 2008; 14(3):279-86.
  44. Mukherjee S, Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology 2008; 134(6):1777-88.
  45. Mathe Z, Tagkalos E, Paul A et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011; 91(5):575-82.
  46. Bellido CB, Martinez JM, Artacho GS et al. Have we changed the liver retransplantation survival? Transplant Proc 2012; 44(6):1526-9.
  47. Remiszewski P, Kalinowski P, Dudek K et al. Influence of selected factors on survival after liver retransplantation. Transplant Proc 2011; 43(8):3025-8.
  48. Hong JC, Kaldas FM, Kositamongkol P et al. Predictive index for long-term survival after retransplantation of the liver in adult recipients: analysis of a 26-year experience in a single center. Ann Surg 2011; 254(3):444-8; discussion 48-9.
  49. Clavien PA, Lesurtel M, Bossuyt PM et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13(1):e11-22.
  50. Murray KF, Carithers RL, Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41(6):1407-32.
  51. Steinmuller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87(1):47-62.
  52. National Comprehensive Cancer Network. NCCN guidelines on hepatobiliary cancers; Version 2:2012. Available online at: http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Last accessed August, 2012.
  53. Newsome PN, Allison ME, Andrews PA et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012; 61(4):484-500.
  54. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) Pub. 100.3 Liver Transplantation. NCD Section 260.1 (adult) and 260.2 (pediatric).

 

Codes

Number

Description

CPT 

47133 

Donor hepatectomy, with preparation and maintenance of allograft; from cadaver donor 

 

47135 

Liver allotransplantation; orthotopic; partial or whole, from cadaver or living donor, any age 

 

47136 

Liver allotransplantation; heterotopic, partial or whole, from cadaver or living donor, any age 

 

47140–47142 

Donor hepatectomy from living donor, code range 

  47143-47145  Backbench standard preparation of cadaver liver graft, code range 
  47146-47147  Backbench reconstruction of cadaver or living donor liver graft, code range 

ICD-9 Procedure 

00.91

Transplant from live related donor (used with code for transplant procedure) 

  00.92 Transplant from live non-related donor (used with code for transplant procedure) 
  00.93 Transplant from cadaver (used with code for transplant procedure) 
 

50.22 

Partial hepatectomy 

 

50.4 

Total hepatectomy 

 

50.51 

Auxiliary liver transplant (leaving patient’s own liver in situ) 

 

50.59 

Other transplant of liver 

ICD-9 Diagnosis 

V59.6 

Liver donor 

 

070.0 – 070.13

Viral hepatitis A code range 

 

070.20 – 070.33 

Viral hepatitis B code range 

 

070.41 

Acute or unspecified hepatitis C with hepatic coma 

 

070.44 

Chronic hepatitis C with hepatic coma 

 

070.51 

Acute or unspecified hepatitis C without mention of hepatic coma 

 

070.54 

Chronic hepatitis C without mention of hepatic coma 

 

070.59 

Other specified viral hepatitis without mention of hepatic coma 

 

070.9 

Unspecified viral hepatitis without mention of hepatic coma 

 

121.1 

Biliary cirrhosis due to Clonorchiasis 

 

121.3 

Biliary cirrhosis due to Fascioliasis 

 

155.0 

Malignant neoplasm of liver 

 

270.0 – 270.9 

Disorders of amino-acid transport and metabolism 

 

271.0 – 271.9 

Disorders of carbohydrate transport and metabolism 

 

272.0 – 272.9 

Disorders of lipoid metabolism 

 

275.0 

Disorders of iron metabolism 

 

275.1 

Disorders of copper metabolism 

 

277.1 

Disorders of porphyrin metabolism 

 

277.30- 277.39 

Amyloidosis code range 

 

277.6 

Other deficiencies of circulating enzymes 

 

277.9 

Unspecified disorder of metabolism 

 

285.0 

Sideroblastic anemia 

 

356.0 

Hereditary peripheral neuropathy 

 

357.4 

Polyneuropathy in other diseases classified elsewhere (Note: code is used in conjunction with 277.3 to indicate amyloid polyneuropathy) 

 

453.0 

Budd-Chiari syndrome 

 

459.9 

Unspecified circulatory system disorder 

 

571.6 

Biliary cirrhosis 

  571.8 Other chronic nonalcoholic liver disease (includes non-alcoholic steatohepatitis cirrhosis

 

573.1 

Hepatitis in viral diseases classified elsewhere (Note: underlying disease must be coded first with this code as secondary) 

 

573.2 

Hepatitis in other infectious diseases classified elsewhere (Note: underlying disease must be coded first with this code as secondary) 

 

573.3 

Hepatitis, unspecified 

 

576.1 

Cholangitis 

 

576.2 

Obstruction of bile duct 

 

576.8 

Other specified disorders of biliary tract 

 

751.62 

Congenital cystic disease of liver 

 

864.00 – 864.19 

Injury to liver code range 

  996.82 Complications of transplanted organ, liver (includes failure and rejection)
ICD-10-CM (effective 10/1/13)  B15.0 – B15.9 Acute hepatitis A; code range  
   B16.0 – B16.9 Acute hepatitis B; code range  
   B17.0 – B17.9 Other acute viral hepatitis; code range  
   B18.0 – B18.9 Chronic viral hepatitis; code range  
   B19.0 – B19.9 Unspecified viral hepatitis; code range  
   B25.1 Cytomegaloviral hepatitis  
   B66.1 Clonorchiasis  
   B66.5 Fasciolopsiasis  
   C22.0 – C22.9 Malignant neoplasm of liver and intrahepatic bile ducts; code range  
   D64.0 – D64.9 Other anemias; code range  
   D81.810 Biotinidase deficiency  
   D84.0 – D84.9 Other immunodeficiencies; code range  
   E72.00 – E72.09 Disorders of amino-acid metabolism; code range  
   E74.00 – E74.9 Other disorders of carbohydrate metabolism; code range  
   E78.0 – E78.9 Disorders of lipoprotein metabolism and other lipidemias; code range  
   E80.0 – E80.7 Disorders of porphyrin and billirubin metabolism; code range  
   E83.0 – E83.09 Disorders of copper metabolism; code range  
    E83.1 – E83.19 Disorders of iron metabolism; code range  
    E85.0 – E85.9 Amyloidosis; code range  
    E88.9 Metabolic disorder, unspecified  
   G60.0 – G60.9 Hereditary and idiopathic neuropathy; code range  
  174.8 Embolism and thrombosis of other arteries (includes hepatic artery thrombosis)
  I82.0 Budd-Chiari syndrome  
  I99.9 Unspecified disorder of circulatory system  
  K71.10 – K71.9 Toxic liver disease  
   K74.0 – K74.69  Fibrosis and cirrhosis of liver; code range  
  K75.81 Nonalcoholic steatohepatitis (NASH)
   K77 Liver disorders in diseases classified elsewhere (code first underlying disease)  
   K83.0 – K83.9 Other diseases of biliary track; code range  
   Q44.6 Congenital Cystic disease of liver  
   S36.12xA - S36.13xS Injury of liver and gallbladder and bile duct; code range  
  T86.41 Liver transplant rejection
  T86.42 Liver transplant failure
   Z52.6 Liver donor  
ICD-10-PCS (effective 10/1/13)  0FB00ZZ, 0FB03ZZ, 0FB04ZZ Surgical, excision, liver, code by approach (open, percutaneous or percutaneous endoscopic)  
   0FB10ZZ, 0FB13ZZ, 0FB14ZZ, 0FB20ZZ, 0FB23ZZ, 0FB24ZZ Surgical, excision, lobe of liver, code by body part (right or left) and approach (open, percutaneous or percutaneous endoscopic)  
   0FT00ZZ, 0FT04ZZ Surgical, resection, liver, code by approach (open or percutaneous endoscopic)  
   0FY00Z0, 0FY00Z1 Surgical, transplantation, liver, open, code by qualifier (allogeneic or syngeneic) 

Type of Service 

Surgery 

Place of Service 

Inpatient 

 


Index

Hepatic Transplant
Liver Transplant
Transplant, Liver

 


Policy History

Date Action Reason
12/01/95 Add to Surgery section New policy
07/31/96 Replace policy Policy guideline change
01/30/98 Replace policy Reviewed with changes; new indications
12/15/00 Replace policy Reviewed with changes; new policy statement on adult-to-adult living-related donors
05/15/02 Replace policy Reviewed, policy statement unchanged; information added regarding MELD and PELD system for prioritizing recipients on waiting list; additional information on living-related donors added
10/9/03 Replace policy Reviewed with literature search; policy statement unchanged; information added on liver transplant in HIV+ recipients. New CPT codes for living donor hepatectomy added
02/25/04 Replace policy Additional criteria added to Policy Guidelines to be consistent with other transplant policies; no change in policy statement; no further review done
04/1/05 Replace policy Policy revised; HIV positivity as an investigational indication for transplantation deleted; additional information provided in Rationale section
04/25/06 Replace policy Policy updated with literature search; no change in policy statement
06/14/07 Replace policy Policy updated with literature search; no change in policy statements. Reference numbers 21-34 added.
11/13/08 Replace policy  Policy updated with literature search, reference numbers 35 to 40 added. Policy statements unchanged. 
09/01/11 Replace policy Policy updated with literature search, reference numbers 15, 23-24, 34, 38 and 40-41 added. Policy statements for medically necessary indications unchanged; neuroendocrine tumor metastases added to investigational statement. Policy statements on hepatocellular carcinoma that has extended beyond the liver and ongoing alcohol and/or drug abuse moved from investigational to not medically necessary. Removed “Patients with an active infection” from the investigational policy statement.
01/10/13 Replace policy Policy updated with literature search; clinical input reviewed; non-alcoholic steatohepatitis cirrhosis added to the medically necessary policy statement; a statement added that retransplantation may be considered medically necessary; a statement added that hilar cholangiocarcinoma may be considered medically necessary. Intrahepatic cholangiocarcinoma was added to the investigational policy statement. Reference numbers 4-5, 19, 29, 31-32, 46-49 and 53 added.
03/14/13 Replace policy - correction only Policy History from 1/10/13 corrected. Correction in the Policy Guidelines paragraph on patients with familial amyloid polyneuropathy – “MELD/PELD exception criteria and scores may apply to these cases.”